Lupin receives EIR from USFDA for its Aurangabad manufacturing facility
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
inspection
Dr. Reddy’s receives EIR for FTO-3 Bachupally plant
During the inspection, the facility received 10 observations
Lupin announces resolution of USFDA warning letter for its two facilities
This is after the satisfactory evaluation of the corrective actions taken by the company in response to the warning letter that…
Indoco’s Baddi facility receives GMP certification from EU Health Authority
The Agency had conducted an inspection at Indoco’s manufacturing facility for solid oral dosage form from April 20 - 24, 2023
USFDA concludes inspection at Zydus’ Ahmedabad facility
The cGMP inspection concluded with nil observations
Lupin’s Somerset facility gets 13 observations post US FDA inspection
The company does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of…
Lupin’s Pithampur Unit-1 facility receives EIR from US FDA
The inspection for the facility was conducted by the US FDA between February 3, 2020 and February 11, 2020 and concluded with two…
Lupin’s Nagpur Facility Receives EIR from US FDA
The inspection for the facility was carried out by the US FDA between January 6, 2020 and January 10, 2020
Lupin’s Aurangabad Facility Receives EIR from US FDA
The inspection for the facility was carried out between February 10, 2020 and February 14, 2020 and concluded with no observations
Alembic Pharma receives four observations from USFDA for Panelav facility
"The US Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals general oral solid…